Dr. Matthew L. Ulrickson, MD

Dr. Ulrickson practices at Banner Gateway Medical Center in Gilbert, Arizona, part of Banner Health.

Dr. Ulrickson's NPI, 1790980316, was assigned on June 15, 2007. Dr. Ulrickson holds Arizona license 47540.

Dr. Ulrickson's primary practice is Banner Gateway Medical Center, at 1900 North Higley Road, Gilbert, AZ 85234 in Maricopa County. The practice phone is (480) 543-2000.

Dr. Ulrickson's primary practice is Banner Gateway Medical Center in Gilbert, Arizona, part of Banner Health. Dr. Ulrickson is also affiliated with Banner Thunderbird Medical Center. The medical group on file is Banner Cancer Center Specialists LLC. Dmand AI also links Dr. Ulrickson to 1 more group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ulrickson practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ulrickson's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ulrickson is licensed in Arizona.

CMS data shows 389 Medicare services from Dr. Ulrickson across 6 procedure codes in 2024, for 143 Medicare patients. Medicare paid $33,092 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 143 Medicare patients who saw Dr. Ulrickson in 2024. The largest group is 65 to 74, with 82 patients. 75% of them have high blood pressure, and 69% have high cholesterol. Their average risk score is 3.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ulrickson's median patient age at 62, with 45% women.

In 2024, Dr. Ulrickson wrote 1,386 Medicare Part D claims for 144 patients. 73% of them were for generic drugs. CMS names the drug for 1,106 of them, across 34 drugs with 11 or more claims each, at $4,333,912 in total drug cost. In 2023, CMS named 1,159 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Ulrickson for performance year 2024, reported as part of a group. Dr. Ulrickson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ulrickson as offering telehealth.

Dmand AI links 19 papers to Dr. Ulrickson, published from 2012 to 2024. 2024 was the busiest year, with 4. The most frequent topics are Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse and Antigens, CD19. Dr. Ulrickson has published most often in Blood. Dr. Ulrickson's most frequent co-authors are Sattva S. Neelapu, MD, Peter A. Riedell and Julio C. Chavez, MD.

Dmand AI links Dr. Ulrickson to 4 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Lymphoma, Follicular, Blastic Plasmacytoid Dendritic Cell Neoplasm and Carcinoma, Merkel Cell.

CMS Open Payments shows 99 general payments to Dr. Ulrickson from 24 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 45% of the total. Incyte Corporation paid the most, $22,885.